Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researcher Taking Shot at Flu Vaccine That's More Effective, Easier to Make

Published: Monday, February 11, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
In the midst of an unusually deadly flu season and armed with a vaccine that only offers partial protection, researcher is working on a flu vaccine that overcomes the need to predict which strains will hit each year.

This year's vaccine is 62 percent effective or "moderately" effective against the current flu strains, according to early estimates from the Centers for Disease Control and Prevention. Flu-related deaths this season have reached an epidemic level and include 45 children, according to the most recent report.

Suresh Mittal, a professor of comparative pathobiology in Purdue's College of Veterinary Medicine, is applying a method he developed for an avian flu vaccine to create a more universal seasonal flu vaccine. The vaccine's protection could persist through different strains and mutations of the influenza virus and would not be dependent on accurate predictions of the strains expected each season, he said.

"This method allows us to create a vaccine that targets core parts of the influenza virus that are found across all strains and don't mutate or change quickly," Mittal said. "It also allows us to target multiple parts of the virus, so that even if the virus adapts to one line of attack, there are others that will still work to prevent the illness."

The method uses a harmless adenovirus as a vector to deliver influenza virus genes into the body where they create a two-fold immune response of antibody and cell-based protection. The adenovirus releases the genes inside the host cells, which then create proteins that lead to the creation of antibodies and special T-cells primed to kill influenza virus and any cells infected by it.

"This method works beyond that of the current vaccine, in which the body responds to inactivated virus proteins injected into a muscle," Mittal said. "Getting the influenza virus genes inside the cells better mimics an infection and leads to a more powerful and multifaceted immune response, so we are better prepared to fend off a true infection."

Any genes important to influenza virus protection can be incorporated into the adenovirus vector, and it can be designed to expose the immune system to components from both the surface and deep within the virus. In this way the immune system can be primed to recognize portions of the virus that are the same across all strains and those that are more difficult for the virus to change as it adapts to the immune system attack, he said.

The new vaccine also has manufacturing advantages over current methods because the vector is easily grown in cell culture. The current flu vaccine depends on the growth of influenza viruses in chicken eggs.

"Sometimes the virus strains selected for the year's vaccine do not grow well in an egg and that can lead to delays or shortages of the vaccine," Mittal said. "The new method depends only on the growth of the virus vector, which we know how to grow quite well. The influenza strains we select to include have no effect on the growth or the amount of vaccine that can be made."

Mittal said vaccination is critical to save lives.

"We don't think of the flu as a killer, but it kills around 35,000 people each year," he said. "Even when the flu vaccine isn't a perfect match, it still offers the best protection. It also is important to get vaccinated to help prevent the spread of the virus to those who are too young or too sick to be vaccinated themselves."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Zika Virus Structure Revealed
Team at Purdue becomes the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.
Monday, April 04, 2016
Purdue Researcher's New 'Tool for the Organic Chemist Toolbox' Licensed to Sigma-Aldrich
U.S. patent for a safer, easier and "greener" method to incorporate fluorine into organic compounds has been licensed to a subsidiary of Sigma-Aldrich Corporation.
Friday, May 24, 2013
Bird Flu Expert Working on Vaccine that Protects Against Multiple Strains
As the bird flu outbreak in China worsens, a Purdue University expert is working on vaccines that offer broader protection against multiple strains of the virus.
Friday, May 10, 2013
Discovery Points to New Approach to Fight Dengue Virus
Researchers have discovered that rising temperature induces key changes in the dengue virus when it enters its human host, suggests new approach for designing vaccines against the aggressive mosquito-borne pathogen.
Monday, April 15, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!